Cosmo Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Cosmo Pharmaceuticals has been growing earnings at an average annual rate of 63%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 20.5% per year. Cosmo Pharmaceuticals's return on equity is 13.8%, and it has net margins of 37.5%.
Key information
63.0%
Earnings growth rate
64.3%
EPS growth rate
Pharmaceuticals Industry Growth | 16.3% |
Revenue growth rate | 20.5% |
Return on equity | 13.8% |
Net Margin | 37.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)
May 20Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Mar 07Revenue & Expenses Breakdown
How Cosmo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 185 | 70 | 37 | 20 |
31 Mar 24 | 139 | 32 | 34 | 19 |
31 Dec 23 | 93 | -5 | 31 | 18 |
30 Sep 23 | 99 | 3 | 25 | 17 |
30 Jun 23 | 104 | 11 | 20 | 16 |
31 Mar 23 | 103 | 14 | 20 | 16 |
31 Dec 22 | 102 | 17 | 20 | 15 |
30 Sep 22 | 90 | 26 | 16 | 13 |
30 Jun 22 | 78 | 35 | 13 | 11 |
31 Mar 22 | 72 | 28 | 12 | 11 |
31 Dec 21 | 65 | 22 | 11 | 11 |
30 Sep 21 | 64 | 6 | 14 | 13 |
30 Jun 21 | 63 | -11 | 17 | 14 |
31 Mar 21 | 62 | -9 | 18 | 14 |
31 Dec 20 | 61 | -8 | 19 | 14 |
30 Sep 20 | 64 | -7 | 21 | 14 |
30 Jun 20 | 67 | -7 | 24 | 15 |
31 Mar 20 | 65 | -16 | 30 | 15 |
31 Dec 19 | 62 | -24 | 35 | 15 |
30 Sep 19 | 56 | -28 | 39 | 14 |
30 Jun 19 | 50 | -31 | 42 | 14 |
31 Mar 19 | 58 | -24 | 46 | 12 |
31 Dec 18 | 66 | -18 | 51 | 10 |
30 Sep 18 | 69 | -20 | 52 | 10 |
30 Jun 18 | 73 | -23 | 54 | 9 |
31 Mar 18 | 70 | -28 | 50 | 9 |
31 Dec 17 | 68 | -32 | 46 | 9 |
30 Sep 17 | 68 | -18 | 38 | 9 |
30 Jun 17 | 69 | -4 | 31 | 9 |
31 Mar 17 | 69 | 8 | 23 | 8 |
31 Dec 16 | 68 | 19 | 16 | 7 |
30 Sep 16 | 70 | 18 | 13 | 10 |
30 Jun 16 | 72 | 16 | 10 | 13 |
31 Mar 16 | 66 | 132 | 16 | 18 |
31 Dec 15 | 61 | 248 | 23 | 23 |
30 Sep 15 | 60 | 241 | 26 | 23 |
30 Jun 15 | 59 | 234 | 29 | 23 |
31 Mar 15 | 69 | 154 | 23 | 21 |
31 Dec 14 | 80 | 73 | 17 | 19 |
30 Sep 14 | 76 | 78 | 14 | 20 |
30 Jun 14 | 72 | 82 | 10 | 21 |
31 Mar 14 | 65 | 75 | 9 | 19 |
31 Dec 13 | 57 | 69 | 8 | 18 |
Quality Earnings: COPN has high quality earnings.
Growing Profit Margin: COPN's current net profit margins (37.5%) are higher than last year (10.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COPN has become profitable over the past 5 years, growing earnings by 63% per year.
Accelerating Growth: COPN's earnings growth over the past year (541.8%) exceeds its 5-year average (63% per year).
Earnings vs Industry: COPN earnings growth over the past year (541.8%) exceeded the Pharmaceuticals industry 9.5%.
Return on Equity
High ROE: COPN's Return on Equity (13.8%) is considered low.